BiotechTube

Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Von Willebrand Disease, Type 3

Conditions

Von Willebrand Disease, Type 3

Trial Timeline

Jun 27, 2025 → Mar 30, 2029

NCT ID
NCT06998524

About Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents

Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents is a phase 3 stage product being developed by Roche for Von Willebrand Disease, Type 3. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06998524. Target conditions include Von Willebrand Disease, Type 3.

What happened to similar drugs?

4 of 6 similar drugs in Von Willebrand Disease, Type 3 were approved

Approved (4) Terminated (0) Active (2)
✅Blood coagulation Factor VIII and vWF, humanCSLApproved
✅VoncentoCSLApproved
✅Alphanate SD/HTGrifolsApproved
✅plasma-derived FVIII/VWF concentrateGrifolsApproved
🔄BiostateCSLPhase 3
🔄BiostateCSLPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06998524Phase 3Recruiting

Competing Products

14 competing products in Von Willebrand Disease, Type 3

See all competitors
ProductCompanyStageHype Score
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex ConcentrateRochePre-clinical
33
Neumega (Oprelvekin, Interleukin 11, IL-11)PfizerPhase 2
27
Oprelvekin, Interleukin 11, IL-11PfizerPhase 2
35
recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11PfizerPhase 2
35
efanesoctocog alfa (BIVV001)SanofiPhase 1
29
BiostateCSLPhase 3
40
Voncento®CSLPre-clinical
26
Blood coagulation Factor VIII and vWF, humanCSLApproved
43
Biostate® + Biostate®CSLPhase 2/3
38
VWF/FVIII productsCSLPre-clinical
26
BiostateCSLPhase 3
40
VoncentoCSLApproved
43
Alphanate SD/HTGrifolsApproved
44
plasma-derived FVIII/VWF concentrateGrifolsApproved
47